Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk is facing serious pressure from a powerful ... whether the stock is still worth buying for a long-term hold. The bull thesis isn't what it used to be Novo is currently in a golden ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options ... for brokerages given its easy-to-integrate API suite and easy-to-consume content.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was ...